- Home
- TXN vs AZN Comparison
TXN vs AZN Comparison
Compare TXN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | AZN |
|---|---|---|
| Founded | 1930 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4B | 250.7B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TXN | AZN |
|---|---|---|
| Price | $299.87 | $186.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 35 | 12 |
| Target Price | ★ $336.86 | $208.08 |
| AVG Volume (30 Days) | ★ 7.9M | 3.0M |
| Earning Date | 10-21-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.02% | 1.73% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 6.44 | N/A |
| Revenue | ★ $17,682,000,000.00 | N/A |
| Revenue This Year | $26.68 | $7.90 |
| Revenue Next Year | $17.32 | $6.38 |
| P/E Ratio | $46.61 | ★ $31.91 |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $152.73 | $87.62 |
| 52 Week High | $334.03 | $212.71 |
Technical Indicators
Market Signals| Indicator | TXN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 65.63 |
| Support Level | $273.89 | $180.98 |
| Resistance Level | $312.81 | $193.96 |
| Average True Range (ATR) | 12.50 | 3.67 |
| MACD | -1.24 | 1.22 |
| Stochastic Oscillator | 62.87 | 75.90 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.